Skip to Content

CSL focused on creating medical breakthroughs

Fri 24 August 2018 09:20 AM Stocks to watch

Recent articles

Following the healthcare company’s FY 18 results, CSL’s Chief Financial Officer David Lamont and nabtrade’s Customer Insights Manager Vishal Teckchandani discuss:

  • Data insights on how nabtrade customers are investing in CSL,
  • Why investors should focus on the company's research & development activities,
  • If CSL has an appetite for a stock split, and
  • The CSL-112 trial, which is the largest trial undertaken by CSL for individuals who have suffered a heart attack. 

Note: The article referred to in the video can be viewed here.

 

EMVision

Medical disruptor trials imaging technology

Dr. Ron Weinberger, CEO of the recently listed EMVision Medical Devices, discusses the company’s ambition to bring portable scanning technology directly to patients.

29 March 2019 Stocks to watch
afterpay

Afterpay to double down in US, target travellers

Afterpay Executive Director, David Hancock, discusses the recent Senate inquiry, competition in the sector, why the US has become its priority market and ‘PLAY’ – its latest innovation targeting travellers.

14 March 2019 Stocks to watch
mte-santos

Santos focused on disciplined growth, cash generation

Santos CEO Kevin Gallagher says he's focused on disciplined growth leveraging existing infrastructure and delivering a low-cost, reliable and high performance business.

4 March 2019 Stocks to watch
a2mmm

The a2 Milk Company to invest for further growth

The a2 Milk Company’s Managing Director and CEO, Jayne Hrdlicka, discusses the dairy nutrition company’s recent results, its target markets, what it plans to do with its cash balance and competition from Nestle.

1 March 2019 Stocks to watch